Arjola K. Cosper

TL;DR: Detailed genetic and histological analysis of 37 patients with drug-resistant non–small cell lung cancers carrying EGFR mutations provides new insights into the shifting sands of drug resistance evolution in lung cancers and suggests that serial biopsies may be essential in the quest to reverse or even prevent the development ofdrug resistance.

TL;DR: SNaPshot molecular profiling identified novel genetic changes in SDCs, expanded the therapeutic options for patients with this rare tumor, and is changing SDC management at the authors' institution, highlighting the importance of using broad-based genetic profiling to expedite the identification of effective-targeted therapies for patientsWith rare malignancies.

TL;DR: PI3K pathway activation may drive tumorigenesis in a subset of MCC and screening these tumors for PIK3CA mutations could help identify patients who may respond to treatment with PI3K pathways inhibitors, under active clinical development.

TL;DR: The single most sensitive test to identify astrocytoma is fluorescence insitu hybridization for chromosome 7 gain (76.2%) and the combination of p53 and mutant IDH1 IHC provides a higher sensitivity than either test alone (47.4%) and offers a practical initial approach for the surgical pathologist.

TL;DR: Investigating whether apocrine-eccrine carcinomas express hormonal receptors or possess activation of oncogenic pathways that can be targeted by available chemotherapeutic agent with PI3K/Akt/mTOR pathway inhibitors, currently in clinical testing, may be of clinical interest.